IAC regimen
|
WikiDoc Resources for IAC regimen |
|
Articles |
|---|
|
Most recent articles on IAC regimen Most cited articles on IAC regimen |
|
Media |
|
Powerpoint slides on IAC regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on IAC regimen at Clinical Trials.gov Clinical Trials on IAC regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on IAC regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on IAC regimen Discussion groups on IAC regimen Patient Handouts on IAC regimen Directions to Hospitals Treating IAC regimen Risk calculators and risk factors for IAC regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for IAC regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: Idarubicin-Ara C-Cladribine regimen; Idarubicin-Cytarabine-Cladribine regimen
Overview
IAC regimen refers to a regimen consisting of idarubicin, cytarabine (Ara-C), and cladribine used to treat acute myelogenous leukemia.[1]
Regimen
IIdrarubicin
ACytarabine (Ara-C)
CCladribin
Indications
References
- ↑ 1.0 1.1 Juliusson G, Höglund M, Karlsson K, Löfgren C, Möllgård L, Paul C; et al. (2003). "Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A randomized population-based phase II study". Br J Haematol. 123 (5): 810–8. PMID 14632771.